{"title": "Una vacuna china contra la COVID-19 en pruebas induce respuesta inmune en mayores de 60 a\u00f1os", "author": "EFE", "url": "https://theobjective.com/sociedad/2020-10-16/una-vacuna-china-contra-la-covid-19-en-pruebas-induce-respuesta-inmune-en-mayores-de-60-anos/", "hostname": "theobjective.com", "description": "China tiene en marcha varias candidatas a vacuna contra la COVID-19, una de ellas basada en el virus SARS-CoV-2 inactivado. Ahora, resultados preliminares", "sitename": "The Objective", "date": "2020-10-16", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Una vacuna china contra la COVID-19 en pruebas induce respuesta inmune en mayores de 60 a\u00f1os\nChina tiene en marcha varias candidatas a vacuna contra la COVID-19, una de ellas basada en el virus SARS-CoV-2[contexto id=\u00bb460724\u2033] inactivado. Ahora, resultados preliminares de los ensayos cl\u00ednicos constatan su seguridad y que induce respuesta inmunol\u00f3gica en voluntarios sanos, tambi\u00e9n en mayores de 60 a\u00f1os.\nPor qu\u00e9 es importante: proteger a las personas mayores es un objetivo clave para el \u00e9xito de la vacuna contra la COVID-19, ya que este grupo tiene un mayor riesgo de padecer una enfermedad grave. Sin embargo, las vacunas a veces son menos eficaces en ellos porque el sistema inmunol\u00f3gico se debilita con la edad. La vacuna fue segura y bien tolerada en todas las dosis probadas, sin que se notificaran reacciones adversas graves. El efecto secundario m\u00e1s com\u00fan fue el dolor en el lugar de la inyecci\u00f3n.\nLos experimentos (en fase 1/2 de ensayos cl\u00ednicos) se llevaron a cabo en China entre el pasado 29 de abril y 30 de julio y contaron con la participaci\u00f3n de m\u00e1s de 600 voluntarios sanos. Los resultados de estos ensayos se publican en The Lancet Infectious Diseases.\nLos ensayos de esta candidata a vacuna (BBIBP-CorV) incluyeron a participantes de entre 18 y 80 a\u00f1os de edad, y encontraron que las respuestas de anticuerpos fueron inducidas en todos ellos. Los participantes de 60 a\u00f1os y de m\u00e1s edad tardaron m\u00e1s en responder; 42 d\u00edas llev\u00f3 detectar los anticuerpos, en comparaci\u00f3n con los 28 d\u00edas en los participantes de 18 a 59 a\u00f1os.\nLos niveles de anticuerpos tambi\u00e9n fueron m\u00e1s bajos en los de 60 a 80 a\u00f1os en comparaci\u00f3n con el otro grupo (el t\u00edtulo medio de anticuerpos neutralizantes 42 d\u00edas despu\u00e9s de recibir la vacuna fue de 228,7 para las personas de 18 a 59 a\u00f1os y de 170,9 para los de 60 a 80 a\u00f1os).\nLos ensayos no se dise\u00f1aron para evaluar la eficacia de la vacuna, por lo que no es posible decir si las respuestas de anticuerpos inducidas por la vacuna BBIBP-CorV son suficientes para proteger de la infecci\u00f3n por SARS-CoV-2, apunta la revista en su nota.\n\u00abEs alentador ver que BBIBP-CorV induce respuestas de anticuerpos en personas de 60 a\u00f1os o m\u00e1s, y creemos que esto justifica una mayor investigaci\u00f3n\u00bb, se\u00f1ala Xiaoming Yang, uno de los autores del estudio, del Instituto de Productos Biol\u00f3gicos de Pek\u00edn.\nActualmente hay 42 vacunas contra la COVID-19 en ensayos cl\u00ednicos y algunas ya han demostrado ser seguras y provocar respuesta inmunitaria en las fases iniciales de los ensayos cl\u00ednicos, recuerda la revista. Var\u00edan en funci\u00f3n de su tipolog\u00eda y entre ellas est\u00e1n las vacunas inactivadas, como la de este estudio, que se basa en una muestra del virus que se aisl\u00f3 de un paciente de China.\nLas reservas del virus se cultivaron en el laboratorio utilizando l\u00edneas celulares y luego se inactivaron utilizando una sustancia qu\u00edmica llamada beta-propionolactona. Seg\u00fan los ensayos, en los que a un n\u00famero de participantes se les administr\u00f3 placebo, las mayores respuestas de anticuerpos se obtuvieron con dos dosis de la vacuna en los d\u00edas 0 y 21 o 0 y 28.\nPara Yang, estos hallazgos indican que una inyecci\u00f3n de refuerzo ser\u00eda necesaria para lograr las mayores respuestas de anticuerpos contra el SARS-CoV-2 y podr\u00eda ser importante para la protecci\u00f3n. Esto proporciona informaci\u00f3n \u00fatil para un ensayo en fase 3.\nLos autores se\u00f1alan algunas limitaciones del estudio, entre ellas la corta duraci\u00f3n del seguimiento, de s\u00f3lo 42 d\u00edas, y tambi\u00e9n que el estudio no inclu\u00eda a ni\u00f1os y adolescentes menores de 18 a\u00f1os. Los ensayos con estos grupos se llevar\u00e1n a cabo cuando se complete el an\u00e1lisis de los datos con adultos.", "language": null, "image": "https://theobjective.com/wp-content/uploads/2020/10/una-vacuna-china-contra-la-covid-19-en-pruebas-induce-respuesta-inmune-en-mayores-de-60-anos.jpg", "pagetype": "article", "links": ["https://theobjective.com", "https://theobjective.com/newsletters", "https://theobjective.com/apoya-a-the-objective", "https://theobjective.com", "https://theobjective.com", "https://theobjective.com/newsletters", "https://theobjective.com/apoya-a-the-objective", "https://theobjective.com", "https://twitter.com/TheObjective_es", "https://www.instagram.com/theobjective_Es/", "https://www.facebook.com/theobjective.esp", "https://www.youtube.com/c/TheObjective_es", "https://open.spotify.com/user/theobjective_es?si=m4YyKsRFSKaAd11iC1pJrA", "https://es.linkedin.com/company/the-objective-media", "https://medium.com/@TheObjective", "https://www.tiktok.com/@theobjective", "https://theobjective.com/", "https://theobjective.com/espana/", "https://theobjective.com/etiqueta/elecciones-generales/", "https://theobjective.com/espana/politica/", "https://theobjective.com/espana/tribunales/", "https://theobjective.com/espana/andalucia/", "https://theobjective.com/etiqueta/cataluna/", "https://theobjective.com/espana/castilla-y-leon/", "https://theobjective.com/etiqueta/comunidad-de-madrid/", "https://theobjective.com/etiqueta/comunidad-valenciana/", "https://theobjective.com/etiqueta/pais-vasco/", "https://theobjective.com/economia/", "https://theobjective.com/etiqueta/macroeconomia/", "https://theobjective.com/etiqueta/telecos/", "https://theobjective.com/etiqueta/energia/", "https://theobjective.com/etiqueta/transporte/", "https://theobjective.com/etiqueta/banca/", "https://theobjective.com/economia/consumo/", "https://theobjective.com/elsubjetivo/", "https://theobjective.com/elsubjetivo/opinion/", "https://theobjective.com/autor/alvaro-nieto/", "https://theobjective.com/autor/felix-de-azua/", "https://theobjective.com/autor/fernando-savater/", "https://theobjective.com/autor/antonio-cano/", "https://theobjective.com/cultura/", "https://theobjective.com/etiqueta/literatura/", "https://theobjective.com/etiqueta/musica/", "https://theobjective.com/etiqueta/cine/", "https://theobjective.com/etiqueta/arte/", "https://theobjective.com/etiqueta/series/", "https://theobjective.com/sociedad/", "https://theobjective.com/etiqueta/salud/", "https://theobjective.com/sociedad/medioambiente/", "https://theobjective.com/lifestyle/", "https://theobjective.com/etiqueta/moda/", "https://theobjective.com/etiqueta/belleza/", "https://theobjective.com/etiqueta/sexualidad/", "https://theobjective.com/gastronomia/", "https://theobjective.com/etiqueta/recetas/", "https://theobjective.com/etiqueta/vinos/", "https://theobjective.com/etiqueta/restaurantes/", "https://theobjective.com/gente/", "https://theobjective.com/etiqueta/celebrities/", "https://theobjective.com/etiqueta/casa-real/", "https://theobjective.com/internacional/", "https://theobjective.com/etiqueta/guerra-ucrania-rusia/", "https://theobjective.com/deportes/", "https://theobjective.com/etiqueta/futbol/", "https://theobjective.com/etiqueta/formula-1/", "https://theobjective.com/etiqueta/baloncesto/", "https://theobjective.com/etiqueta/tenis/", "https://theobjective.com/etiqueta/golf/", "https://theobjective.com/motor/", "https://theobjective.com/etiqueta/coches/", "https://theobjective.com/etiqueta/motos/", "https://theobjective.com/etiqueta/movilidad/", "https://theobjective.com/etiqueta/dgt/", "https://theobjective.com/tecnologia/", "https://theobjective.com/tecnologia/videojuegos/", "https://theobjective.com/etiqueta/internet/", "https://theobjective.com/etiqueta/smartphones/", "https://theobjective.com/etiqueta/redes-sociales/", "https://theobjective.com/etiqueta/historia/", "https://theobjective.com/etiqueta/historias-de-la-historia/", "https://theobjective.com/medios/", "https://theobjective.com/medios/television/", "https://theobjective.com/medios/radio/", "https://theobjective.com/etiqueta/programas/", "https://theobjective.com/ultimas-noticias/", "https://theobjective.com/videos/", "https://theobjective.com/etiqueta/entrevistas/", "https://theobjective.com/etiqueta/el-purgatorio/", "https://theobjective.com/etiqueta/vidas-cruzadas/", "https://theobjective.com/podcasts/", "https://theobjective.com/etiqueta/al-tanto/", "https://theobjective.com/etiqueta/el-gris-importa/", "https://theobjective.com/etiqueta/sumario-de-tarde/", "https://theobjective.com/galerias/", "https://theobjective.com/productos-recomendados/", "https://informativoscanarias.theobjective.com/", "https://classpaper.theobjective.com/", "https://theobjective.com/quienes-somos/", "https://theobjective.com/principios-y-valores/", "https://theobjective.com/equipo/", "https://theobjective.com/firmas/", "https://theobjective.com/app/", "https://theobjective.com/escuela-ethos/", "https://theobjective.com/newsletters", "https://theobjective.com/apoya-a-the-objective", "https://theobjective.com/sociedad/", "https://theobjective.com/autor/efe/", "https://theobjective.com/autor/efe/", "//www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Ftheobjective.com%2Fsociedad%2F2020-10-16%2Funa-vacuna-china-contra-la-covid-19-en-pruebas-induce-respuesta-inmune-en-mayores-de-60-anos%2F", "//twitter.com/intent/tweet?url=https%3A%2F%2Ftheobjective.com%2Fsociedad%2F2020-10-16%2Funa-vacuna-china-contra-la-covid-19-en-pruebas-induce-respuesta-inmune-en-mayores-de-60-anos%2F&text=Una%20vacuna%20china%20contra%20la%20COVID-19%20en%20pruebas%20induce%20respuesta%20inmune%20en%20mayores%20de%2060%20a%C3%B1os&via=TheObjective_es", "//web.whatsapp.com/send?text=Una%20vacuna%20china%20contra%20la%20COVID-19%20en%20pruebas%20induce%20respuesta%20inmune%20en%20mayores%20de%2060%20a%C3%B1os | The Objective%20https%3A%2F%2Ftheobjective.com%2Fsociedad%2F2020-10-16%2Funa-vacuna-china-contra-la-covid-19-en-pruebas-induce-respuesta-inmune-en-mayores-de-60-anos%2F", "https://www.linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Ftheobjective.com%2Fsociedad%2F2020-10-16%2Funa-vacuna-china-contra-la-covid-19-en-pruebas-induce-respuesta-inmune-en-mayores-de-60-anos%2F&title=Una%20vacuna%20china%20contra%20la%20COVID-19%20en%20pruebas%20induce%20respuesta%20inmune%20en%20mayores%20de%2060%20a%C3%B1os", "//telegram.me/share/url?url=https%3A%2F%2Ftheobjective.com%2Fsociedad%2F2020-10-16%2Funa-vacuna-china-contra-la-covid-19-en-pruebas-induce-respuesta-inmune-en-mayores-de-60-anos%2F&text=Una%20vacuna%20china%20contra%20la%20COVID-19%20en%20pruebas%20induce%20respuesta%20inmune%20en%20mayores%20de%2060%20a%C3%B1os%20The Objective", "/cdn-cgi/l/email-protection#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", "https://theobjective.com/autor/efe/", "https://theobjective.com/autor/efe/", "//www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Ftheobjective.com%2Fsociedad%2F2020-10-16%2Funa-vacuna-china-contra-la-covid-19-en-pruebas-induce-respuesta-inmune-en-mayores-de-60-anos%2F", "//twitter.com/intent/tweet?url=https%3A%2F%2Ftheobjective.com%2Fsociedad%2F2020-10-16%2Funa-vacuna-china-contra-la-covid-19-en-pruebas-induce-respuesta-inmune-en-mayores-de-60-anos%2F&text=Una%20vacuna%20china%20contra%20la%20COVID-19%20en%20pruebas%20induce%20respuesta%20inmune%20en%20mayores%20de%2060%20a%C3%B1os&via=TheObjective_es", "//web.whatsapp.com/send?text=Una%20vacuna%20china%20contra%20la%20COVID-19%20en%20pruebas%20induce%20respuesta%20inmune%20en%20mayores%20de%2060%20a%C3%B1os | The Objective%20https%3A%2F%2Ftheobjective.com%2Fsociedad%2F2020-10-16%2Funa-vacuna-china-contra-la-covid-19-en-pruebas-induce-respuesta-inmune-en-mayores-de-60-anos%2F", "https://www.linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Ftheobjective.com%2Fsociedad%2F2020-10-16%2Funa-vacuna-china-contra-la-covid-19-en-pruebas-induce-respuesta-inmune-en-mayores-de-60-anos%2F&title=Una%20vacuna%20china%20contra%20la%20COVID-19%20en%20pruebas%20induce%20respuesta%20inmune%20en%20mayores%20de%2060%20a%C3%B1os", "//telegram.me/share/url?url=https%3A%2F%2Ftheobjective.com%2Fsociedad%2F2020-10-16%2Funa-vacuna-china-contra-la-covid-19-en-pruebas-induce-respuesta-inmune-en-mayores-de-60-anos%2F&text=Una%20vacuna%20china%20contra%20la%20COVID-19%20en%20pruebas%20induce%20respuesta%20inmune%20en%20mayores%20de%2060%20a%C3%B1os%20The Objective", "/cdn-cgi/l/email-protection#3e014d4b5c545b5d4a036a5b1b0c0e4e4b5b5a5b1b0c0e57504a5b4c5b4d5f4c101010185c515a47036b505f1b0c0e485f5d4b505f1b0c0e5d5657505f1b0c0e5d51504a4c5f1b0c0e525f1b0c0e7d7168777a130f071b0c0e5b501b0c0e4e4c4b5b5c5f4d1b0c0e57505a4b5d5b1b0c0e4c5b4d4e4b5b4d4a5f1b0c0e5750534b505b1b0c0e5b501b0c0e535f47514c5b4d1b0c0e5a5b1b0c0e080e1b0c0e5f1b7d0d1b7c0f514d1b0c0e564a4a4e4d1b0d7f1b0c781b0c784a565b515c545b5d4a57485b105d51531b0c784d515d575b5a5f5a1b0c780c0e0c0e130f0e130f081b0c784b505f13485f5d4b505f135d5657505f135d51504a4c5f13525f135d5148575a130f07135b50134e4c4b5b5c5f4d1357505a4b5d5b134c5b4d4e4b5b4d4a5f135750534b505b135b5013535f47514c5b4d135a5b13080e135f50514d1b0c78", "https://news.google.com/publications/CAAiELumQ8m_nwDuO-xzhLPkxhgqFAgKIhC7pkPJv58A7jvsc4Sz5MYY?ceid=ES:es&oc=3", "https://theobjective.com/etiqueta/china/", "https://theobjective.com/etiqueta/coronavirus/", "https://theobjective.com/etiqueta/pandemias/", "https://theobjective.com/etiqueta/vacunas/", "https://theobjective.com/apoya-a-the-objective/", "https://theobjective.com/tecnologia/2020-10-23/eeuu-autoriza-plenamente-el-antiviral-remdesivir-como-tratamiento-de-la-covid-19/", "https://theobjective.com/tecnologia/2020-10-23/eeuu-autoriza-plenamente-el-antiviral-remdesivir-como-tratamiento-de-la-covid-19/", "https://theobjective.com/sociedad/2020-10-23/castilla-y-leon-aplicara-el-toque-de-queda-entre-las-22-y-las-6-horas-desde-este-sabado/", "https://theobjective.com/sociedad/2020-10-23/castilla-y-leon-aplicara-el-toque-de-queda-entre-las-22-y-las-6-horas-desde-este-sabado/", "https://theobjective.com/sociedad/2020-10-23/el-gobierno-deja-en-el-aire-la-declaracion-del-estado-de-alarma-en-un-consejo-de-ministros-este-fin-de-semana/", "https://theobjective.com/sociedad/2020-10-23/el-gobierno-deja-en-el-aire-la-declaracion-del-estado-de-alarma-en-un-consejo-de-ministros-este-fin-de-semana/", "https://theobjective.com/sociedad/2020-10-23/espana-pierde-control-pandemia-sanidad-19-851-casos/", "https://theobjective.com/sociedad/2020-10-23/espana-pierde-control-pandemia-sanidad-19-851-casos/", "https://theobjective.com/sociedad/2020-10-23/madrid-restringe-las-reuniones-entre-las-0000-y-las-0600-desde-este-sabado/", "https://theobjective.com/sociedad/2020-10-22/la-comunidad-valenciana-anuncia-un-toque-de-queda-entre-la-medianoche-y-las-600/", "https://theobjective.com/sociedad/2020-10-22/la-curva-se-descontrola-sanidad-registra-un-record/", "https://theobjective.com/sociedad/2020-10-22/las-comunidades-aceptan-cerrar-bares-y-tiendas-a-las-2300-en-las-zonas-mas-afectadas-salvo-madrid-y-pais-vasco/", "https://theobjective.com/espana/", "https://theobjective.com/espana/politica/", "https://theobjective.com/espana/tribunales/", "https://theobjective.com/etiqueta/madrid/", "https://theobjective.com/etiqueta/cataluna/", "https://theobjective.com/espana/andalucia/", "https://theobjective.com/economia/", "https://theobjective.com/etiqueta/macroeconomia/", "https://theobjective.com/etiqueta/banca/", "https://theobjective.com/etiqueta/telecos/", "https://theobjective.com/etiqueta/energia/", "https://theobjective.com/etiqueta/transporte/", "https://theobjective.com/elsubjetivo/", "https://theobjective.com/elsubjetivo/opinion/", "https://theobjective.com/autor/alvaro-nieto/", "https://theobjective.com/autor/felix-de-azua/", "https://theobjective.com/autor/fernando-savater/", "https://theobjective.com/autor/antonio-cano/", "https://theobjective.com/sociedad/", "https://theobjective.com/cultura/", "https://theobjective.com/deportes/", "https://theobjective.com/internacional/", "https://theobjective.com/economia/consumo/", "https://theobjective.com/lifestyle/", "https://theobjective.com/gastronomia/", "https://theobjective.com/etiqueta/moda/", "https://theobjective.com/etiqueta/belleza/", "https://theobjective.com/etiqueta/sexualidad/", "https://theobjective.com/gente/", "https://theobjective.com/videos/", "https://theobjective.com/podcasts/", "https://theobjective.com/ultimas-noticias/", "https://theobjective.com/etiqueta/entrevistas/", "https://theobjective.com/branded-content/", "https://theobjective.com/etiqueta/vidas-cruzadas/", "https://theobjective.com/etiqueta/contraluz/", "https://theobjective.com/etiqueta/la-mirilla/", "https://theobjective.com/etiqueta/el-buzon-secreto/", "https://theobjective.com/etiqueta/historias-de-la-historia/", "https://theobjective.com/quienes-somos/", "https://theobjective.com/equipo/", "https://theobjective.com/newsletters/", "https://theobjective.com/apoya-a-the-objective/", "https://theobjective.com/escuela-ethos/", "https://theobjective.com/quienes-somos/", "https://theobjective.com/equipo/", "https://theobjective.com/politica-de-privacidad/", "https://theobjective.com/politica-de-cookies/", "https://theobjective.com/aviso-legal/", "https://theobjective.com/contactanos/", "https://theobjective.com/newsletters", "https://theobjective.com/terminos-y-condiciones", "https://theobjective.com/politica-de-privacidad", "https://theobjective.com"]}